Search results for Alirocumab

Alirocumab, Abbexa, abx831244

Alirocumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PCSK9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.

Alirocumab, Affinityimmuno, ab-131-alirocumab

Alirocumab ELISA Kit, ProteoGenix, KPTX396

Description of Alirocumab ELISA Kit Introduction The Alirocumab ELISA Kit is a highly sensitive and specific diagnostic tool used for the detection and quantification of Alirocumab, a therapeutic antibody used for the treatment of hypercholesterolemia. This kit is designed for research use and provides reliable and accurate results for the measurement of Alirocumab levels in various biological samples. Structure of Alirocumab Alirocumab is a fully human monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein involved in the regulation of low-density lipoprotein (LDL) cholesterol levels. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure with two antigen binding sites, allowing it to bind to PCSK9 with high affinity and specificity. Activity of Alirocumab Alirocumab works by blocking the interaction between PCSK9 and the LDL receptor, which is responsible for removing LDL cholesterol from the bloodstream. By inhibiting this interaction, Alirocumab increases the number of active LDL receptors on the surface of cells, leading to increased clearance of LDL cholesterol from the blood. This results in a significant reduction in LDL cholesterol levels, making Alirocumab an effective therapeutic target for the treatment of hypercholesterolemia. The activity of Alirocumab has been extensively studied in clinical trials, with promising results. In a phase III trial, Alirocumab was shown to significantly reduce LDL cholesterol levels by an average of 61%, compared to placebo. It also demonstrated a favorable safety profile, with no significant adverse effects reported. Application of Alirocumab ELISA Kit The Alirocumab ELISA Kit is a valuable tool for researchers and clinicians studying the efficacy and pharmacokinetics of Alirocumab. It can be used to measure the levels of Alirocumab in various biological samples, including serum, plasma, and cell culture supernatant. One of the main applications of this kit is in pharmacokinetic studies, where it can be used to determine the concentration of Alirocumab in the blood over time. This information is crucial for understanding the drug’s absorption, distribution, metabolism, and excretion in the body. It can also aid in dose optimization and monitoring of treatment response in patients. The Alirocumab ELISA Kit can also be used in preclinical studies to assess the pharmacokinetics of Alirocumab in animal models. This can provide valuable insights into the drug’s behavior in vivo and aid in the development of new formulations or dosing regimens. Furthermore, this kit can be used in clinical trials to assess the immunogenicity of Alirocumab. As with any therapeutic antibody, there is a risk of developing anti-drug antibodies, which can affect the drug’s efficacy and safety. The Alirocumab ELISA Kit can detect the presence of these antibodies in patient samples, allowing for early detection and management of potential immune reactions. Conclusion The Alirocumab ELISA Kit is a highly sensitive and specific diagnostic tool that plays a crucial role in the development and monitoring of Alirocumab as a therapeutic target for hypercholesterolemia. Its accurate and reliable results make it an essential tool for researchers and clinicians studying the pharmacokinetics and immunogenicity of Alirocumab. With the increasing use of Alirocumab in clinical practice, the demand for this kit is expected to grow, making it an indispensable tool in the field of lipid-lowering therapies.

Alirocumab Biosimilar - Research Grade, ichor.bio, ICH4016

Detects human PCSK9. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Alirocumab.

Research Grade Alirocumab (HV275016), abinScience, HV275016